MicroRNA hsa-miR-4674 in Hemolysis-Free Blood Plasma Is Associated with Distant Metastases of Prostatic Cancer

Knyazev, E N; Samatov, Timur R.; Fomicheva, K. A.; Nyushko, K. M.; Alekseev, B. Ya.; Shkurnikov, M. Yu.

doi:10.1007/s10517-016-3358-6

Cited by 30 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, miR-101-3p was claimed to be related to kinds of both non-malignant syndromes (multiple system atrophy [75], hepatopulmonary syndrome [76], cardiac fibroblasts [77], HBV-associated chronic hepatitis [78], Alzheimer [79], pulmonary fibrosis [80], acute kidney injury [81], gestational diabetes mellitus [82]) and, especially, malignant neoplasms [83]. Similarly, miR-22-5p is aberrantly expressed in various cancers, such as prostatic cancer [84], esophageal squamous cell carcinoma [85] and breast cancer [86], together with, among others, polyglutamine diseases such as Huntington's disease [87]. Consistently, searching Vesiclepedia, both miRNAs were reported as embedded in greatly different amounts between EVs from tissue or cancer types.…”

Section: Discussionmentioning

confidence: 99%

miRNA Reference Genes in Extracellular Vesicles Released from Amniotic Membrane-Derived Mesenchymal Stromal Cells

et al. 2020

View full text Add to dashboard Cite

Human amniotic membrane and amniotic membrane-derived mesenchymal stromal cells (hAMSCs) have produced promising results in regenerative medicine, especially for the treatment of inflammatory-based diseases and for different injuries including those in the orthopedic field such as tendon disorders. hAMSCs have been proposed to exert their anti-inflammatory and healing potential via secreted factors, both free and conveyed within extracellular vesicles (EVs). In particular, EV miRNAs are considered privileged players due to their impact on target cells and tissues, and their future use as therapeutic molecules is being intensely investigated. In this view, EV-miRNA quantification in either research or future clinical products has emerged as a crucial paradigm, although, to date, largely unsolved due to lack of reliable reference genes (RGs). In this study, a panel of thirteen putative miRNA RGs (let-7a-5p, miR-16-5p, miR-22-5p, miR-23a-3p, miR-26a-5p, miR-29a-5p, miR-101-3p, miR-103a-3p, miR-221-3p, miR-423-5p, miR-425-5p, miR-660-5p and U6 snRNA) that were identified in different EV types was assessed in hAMSC-EVs. A validated experimental pipeline was followed, sifting the output of four largely accepted algorithms for RG prediction (geNorm, NormFinder, BestKeeper and ΔCt method). Out of nine RGs constitutively expressed across all EV isolates, miR-101-3p and miR-22-5p resulted in the most stable RGs, whereas miR-423-5p and U6 snRNA performed poorly. miR-22-5p was also previously reported to be a reliable RG in adipose-derived MSC-EVs, suggesting its suitability across samples isolated from different MSC types. Further, to shed light on the impact of incorrect RG choice, the level of five tendon-related miRNAs (miR-29a-3p, miR-135a-5p, miR-146a-5p, miR-337-3p, let-7d-5p) was compared among hAMSC-EVs isolates. The use of miR-423-5p and U6 snRNA did not allow a correct quantification of miRNA incorporation in EVs, leading to less accurate fingerprinting and, if used for potency prediction, misleading indication of the most appropriate clinical batch. These results emphasize the crucial importance of RG choice for EV-miRNAs in hAMSCs studies and contribute to the identification of reliable RGs such as miR-101-3p and miR-22-5p to be validated in other MSC-EVs related fields.

show abstract

Section: Discussionmentioning

confidence: 99%

miRNA Reference Genes in Extracellular Vesicles Released from Amniotic Membrane-Derived Mesenchymal Stromal Cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, different miRNAs in different contexts are aberrantly expressed in various cancers, such as prostatic cancer, esophageal squamous cell carcinoma, breast cancer, and gastric cancer. For example, the miR-22 shows different effects in these cancers [80][81][82][83]. DADS can silence HIF-1α (hypoxia inducible factor 1α) via increasing expression of miR-22 to repress VEGF (vascular endothelial growth factor) expression to block angiogenesis, leading to the disruption of cancer progression [79,84].…”

Section: Regulation Of the Mirnas By Dadsmentioning

confidence: 99%

The Progress of Diallyl Disulfide in Anti-Cancer

Lz¹,

Liao²,

Wang³

et al. 2017

Chemotherapy

View full text Add to dashboard Cite

Considerable evidence in recent years suggests that garlic has anti-proliferative effects on various types of cancer. Garlic contains water-soluble and oil-soluble sulfur compounds. Oil-soluble compounds (OSCs), such as diallyl sulfide (DAS), diallyl disulfide (DADS), diallyl trisulfide (DATS) and ajoene are more effective than watersoluble compounds in protection against cancer. DADS, a major organosulfur compound derived from garlic, can reduce carcinogen-induced cancers in experimental animals and inhibit the proliferation of various types of cancer cells. The mechanisms of these action of DADS include activation of metabolic enzymes that detoxify carcinogens, suppression of the formation of DNA adducts, antioxidant effects, regulation of cell-cycle progression, induction of apoptosis, and inhibition of angiogenesis and metastasis. These topics are discussed in depth in this review.

show abstract

“…For instance, the low expression of miR-22 in the serum of patients with ICC (intrahepatic cholangio-carcinoma) and hepatocellular cancer with hepatitis C virus and the malignant pleural effusion of patients with lung adenocarcinoma may well be promising as an independent early diagnostic biomarker for these cancers (63–65). On the contrary, the sustained high expression of miR-22 in the serum of patients with esophageal squamous cell carcinoma, pancreatic cancer and metastatic prostatic cancer may well be a reliable serum biomarker for cancer diagnosis, along with the desirable diagnosis of sensitivity and specificity (2,66,67) (Table I). …”

Section: Mir-22 Is An Independent Biomarker For Cancer Diagnosis mentioning

confidence: 99%

“…Recently, increasing numbers of studies have confirmed that miR-22, to a large extent, determines the destiny of many cancers, to die soon or survive, by the complicated known or unknown mechanisms through targeting and suppressing downstream transcription factors. Frequently, since miR-22 in different contexts are aberrantly expressed upregulation or downregulation in various cancers, such as prostatic cancer, esophageal squamous cell carcinoma, breast cancer, and gastric cancers, thus miR-22 shows different effects in these cancers (2–5), that is, it served not only as a tumor-suppressive miRNA, but also as an oncogenic miRNA to encumber or aggravate cancer formation and malignant transformation (3,6). Besides, reports also showed that miR-22 may prominently influence cancer biological behaviors, such as proliferation, invasion and metastasis (7,8), and it genetically alters expression of numerous related genes (9), which unveils the intrinsic mechanisms of miR-22 in regulating cancer formation by means of multi-approaches and multi-layers, indicating the central roles of miR-22 in manipulating the occurrence and development of different cancers.…”

Section: Introductionmentioning

confidence: 99%

Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review)

Wang

Ding

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

miRNAs (microRNAs) have been validated to play fateful roles in the occurrence and development of cancers by post-transcriptionally targeting 3′-untranslated regions of the downstream gene mRNAs to repress mRNA expression. Mounting investigations forcefully document that not only does miR-22 biologically impinge on the processes of senescence, energy supply, angiogenesis, EMT (epithelial-mesenchymal transition), proliferation, migration, invasion, metastasis and apoptosis, but also it genetically or epigenetically exerts dual (inhibitory/promoting cancer) effects in various cancers via CNAs (copy number alterations), SNPs (single nucleotide polymorphisms), methylation, acetylation and even more momentously hydroxymethylation. Additionally, miR-22 expression may fluctuate with cancer progression in the body fluids of cancer patients and miR-22 could amplify its inhibitory or promoting effects through partaking in positive or negative feedback loops and interplaying with many other related miRNAs in the cascade of events, making it possible for miR-22 to be a promising and complementary or even independent cancer biomarker in some cancers and engendering profound influences on the early diagnosis, therapeutics, supervising curative effects and prognosis.

show abstract

MicroRNA hsa-miR-4674 in Hemolysis-Free Blood Plasma Is Associated with Distant Metastases of Prostatic Cancer

Cited by 30 publications

References 15 publications

miRNA Reference Genes in Extracellular Vesicles Released from Amniotic Membrane-Derived Mesenchymal Stromal Cells

miRNA Reference Genes in Extracellular Vesicles Released from Amniotic Membrane-Derived Mesenchymal Stromal Cells

The Progress of Diallyl Disulfide in Anti-Cancer

Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review)

Contact Info

Product

Resources

About